First patient receives ground-breaking treatment
In January 23-year-old Jake Ternent became the first person with an inherited sight loss condition to be treated in the UK with Luxturna (voretigene neparvovec) for Leber congenital amaurosis (LCA).
Search
Search results
Hope for the future
In this article, we hear Colin's story and the reasons why he has hope for the future.
jCyte have released additional preclinical data regarding jCell
jCyte have released additional preclinical data regarding jCell
How we can support you in your role
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
A week in the life of a researcher
On a typical week in the stem cell lab there are many different experiments going on. Different people work on their individual projects, but we often collaborate to share ideas and help each other.
ReNeuron trial FAQs
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
jCyte update
In spring 2021, the US company jCyte announced detailed results from their successful phase 2b clinical trial of jCell, a stem cell-based treatment for RP.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Aavantgarde Bio Ush1B study at Moorfields
Aavantgarde Bio Ush1B study at Moorfields